Guggenheim Assumes Protara Therapeutics at Buy, Announces Price Target of $22
Portfolio Pulse from richadhand@benzinga.com
Guggenheim analyst Charles Zhu has assumed Protara Therapeutics (NASDAQ:TARA) with a Buy rating and set a price target of $22.
July 10, 2023 | 1:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Protara Therapeutics has been assumed by Guggenheim analyst Charles Zhu with a Buy rating and a price target of $22.
The Buy rating and price target set by Guggenheim analyst Charles Zhu indicates a positive outlook for Protara Therapeutics. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100